⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30123159 | 1.00 | — | — | |
| SCHEMBL2484489 | 0.94 | — | — | |
| SCHEMBL2485552 | 0.92 | — | — | |
| SCHEMBL2455015 | 0.91 | — | — | |
| SCHEMBL2480530 | 0.90 | — | — | |
| SCHEMBL2484196 | 0.90 | — | — | |
| SCHEMBL2481832 | 0.89 | — | — | |
| SCHEMBL2523835 | 0.89 | — | — | |
| SCHEMBL2482313 | 0.88 | — | — | |
| SCHEMBL2485195 | 0.87 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4103161-B1 | COMPOSITIONS AND USES THEREOF | BENEVOLENTAI CAMBRIDGE LTD (GB) | 2023-12-20 | — | — | EP | claimed |
| US-20230149385-A1 | COMPOSITIONS AND USES THEREOF | Benevolentai Cambridge Limited (GB) | 2023-05-18 | — | — | US | claimed |
| EP-4103161-A1 | COMPOSITIONS AND USES THEREOF | BenevolentAI Cambridge Limited (GB) | 2022-12-21 | — | — | EP | claimed |
| CN-115484938-A | Composition and use thereof | 博善人工智能剑桥有限公司 | 2022-12-16 | — | — | CN | claimed |
| EP-2545055-B1 | Imidazo[1,2-a]pyrazine derivatives and their use for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases | JANSSEN PHARMACEUTICA NV (BE) | 2017-08-09 | — | — | EP | claimed |
| US-8859543-B2 | Imidazo[1,2-a]pyrazine derivatives and their use for the prevention or treatment of neurological, psychiatric and metabolic disorders and diseases | JANSSEN PHARMACEUTICA NV (BE) | 2014-10-14 | — | — | US | claimed |
| EP-2545055-A1 | IMIDAZO [1, 2 -A]PYRAZINE DERIVATIVES AND THEIR USE FOR THE PREVENTION OR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC AND METABOLIC DISORDERS AND DISEASES | Janssen Pharmaceutica, N.V. (BE) | 2013-01-16 | — | — | EP | claimed |
| US-20120329792-A1 | IMIDAZO[1,2-a]PYRAZINE DERIVATIVES AND THEIR USE FOR THE PREVENTION OR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC AND METABOLIC DISORDERS AND DISEASES | JANSSEN PHARMACEUTICA NV | 2012-12-27 | — | — | US | claimed |
| WO-2011110545-A1 | IMIDAZO [1, 2 -A] PYRAZINE DERIVATIVES AND THEIR USE FOR THE PREVENTION OR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC AND METABOLIC DISORDERS AND DISEASES | JANSSEN PHARMACEUTICA NV (BE) | 2011-09-15 | — | — | WO | claimed |
| EP-4103161-B1 | COMPOSITIONS AND USES THEREOF | BENEVOLENTAI CAMBRIDGE LTD (GB) | 2023-12-20 | — | — | EP | disclosed |
| US-20230149385-A1 | COMPOSITIONS AND USES THEREOF | Benevolentai Cambridge Limited (GB) | 2023-05-18 | — | — | US | disclosed |
| US-20230149385-A1 | COMPOSITIONS AND USES THEREOF | Benevolentai Cambridge Limited (GB) | 2023-05-18 | — | — | US | disclosed |
| US-20230149385-A1 | COMPOSITIONS AND USES THEREOF | Benevolentai Cambridge Limited (GB) | 2023-05-18 | — | — | US | disclosed |
| EP-4103161-A1 | COMPOSITIONS AND USES THEREOF | BenevolentAI Cambridge Limited (GB) | 2022-12-21 | — | — | EP | disclosed |
| EP-2545055-A1 | IMIDAZO [1, 2 -A]PYRAZINE DERIVATIVES AND THEIR USE FOR THE PREVENTION OR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC AND METABOLIC DISORDERS AND DISEASES | Janssen Pharmaceutica, N.V. (BE) | 2013-01-16 | — | — | EP | disclosed |
| US-20120329792-A1 | IMIDAZO[1,2-a]PYRAZINE DERIVATIVES AND THEIR USE FOR THE PREVENTION OR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC AND METABOLIC DISORDERS AND DISEASES | JANSSEN PHARMACEUTICA NV | 2012-12-27 | — | — | US | disclosed |
| US-20120329792-A1 | IMIDAZO[1,2-a]PYRAZINE DERIVATIVES AND THEIR USE FOR THE PREVENTION OR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC AND METABOLIC DISORDERS AND DISEASES | JANSSEN PHARMACEUTICA NV | 2012-12-27 | — | — | US | disclosed |
| US-20120329792-A1 | IMIDAZO[1,2-a]PYRAZINE DERIVATIVES AND THEIR USE FOR THE PREVENTION OR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC AND METABOLIC DISORDERS AND DISEASES | JANSSEN PHARMACEUTICA NV | 2012-12-27 | — | — | US | disclosed |
| WO-2011110545-A1 | IMIDAZO [1, 2 -A] PYRAZINE DERIVATIVES AND THEIR USE FOR THE PREVENTION OR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC AND METABOLIC DISORDERS AND DISEASES | JANSSEN PHARMACEUTICA NV (BE) | 2011-09-15 | — | — | WO | disclosed |
| WO-2011110545-A1 | IMIDAZO [1, 2 -A] PYRAZINE DERIVATIVES AND THEIR USE FOR THE PREVENTION OR TREATMENT OF NEUROLOGICAL, PSYCHIATRIC AND METABOLIC DISORDERS AND DISEASES | JANSSEN PHARMACEUTICA NV (BE) | 2011-09-15 | — | — | WO | disclosed |